Stoke Therapeutics (STOK) plans to raise $100 million in an initial public offering on Wednesday, June 19th, IPO Scoop reports. The company will issue 6,700,000 shares at a price of $14.00-$16.00 per share.
The company has a market cap of $454 million.
J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.
Stoke Therapeutics provided the following description of their company for its IPO: ” We are pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression. We are developing novel antisense oligonucleotide, or ASO, medicines that target ribonucleic acid, or RNA, and modulate precursor-messenger RNA, or pre-mRNA, splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. We utilize our proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or TANGO, to design ASOs to upregulate the expression of protein by individual genes in a patient. “.
Stoke Therapeutics was founded in 2014 and has 49 employees. The company is located at 45 Wiggins Avenue, Bedford, MA, 01730, US and can be reached via phone at (781) 430-8200 or on the web at http://www.stoketherapeutics.com.
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.